The FDA has classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding, such as immunogenicity, impurities, and insufficient safety evidence for suggested administration routes
In lupus-prone mice, 4-PBA reduces splenomegaly, anti-dsDNA antibodies, and inflammatory cytokines and alleviates lupus nephritis by decreasing albuminuria, renal inflammation, and immune complex deposition
FDA PCAC 2023 What this means practically for research dosage decisions: Doses above 1 mg/day are not supported by efficacy data and appear to produce diminishing returns
Smoking is associated with abdominal obesity, not overall obesity, in men with type 2 diabetes
BPC-157 requires stable storage in controlled environments (lyophilized vials, sealed containers, low-temperature conditions)